Gautam Chukka
Stock Analyst at Chardan Capital
(0.40)
# 4,445
Out of 5,073 analysts
7
Total ratings
n/a
Success rate
-35.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gautam Chukka
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVRD Tvardi Therapeutics | Initiated Coverage: Buy | $8 | $1.02 | +684.31% | 1 | Oct 20, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $25 | $12.62 | +98.10% | 1 | Oct 6, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $240 | $126.58 | +89.60% | 1 | Sep 21, 2026 | |
| ADAG Adagene | Initiated Coverage: Buy | $9 | $2.41 | +273.44% | 1 | Sep 10, 2026 | |
| TENX Tenax Therapeutics | Downgraded: Hold | $27 → $5 | $1.63 | +206.75% | 3 | Aug 11, 2026 |
Tvardi Therapeutics
Oct 20, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.02
Upside: +684.31%
4D Molecular Therapeutics
Oct 6, 2026
Reiterated: Buy
Price Target: $25
Current: $12.62
Upside: +98.10%
Palvella Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $240
Current: $126.58
Upside: +89.60%
Adagene
Sep 10, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $2.41
Upside: +273.44%
Tenax Therapeutics
Aug 11, 2026
Downgraded: Hold
Price Target: $27 → $5
Current: $1.63
Upside: +206.75%